中药ETF(159647)涨近1%，多地政策持续支持中药产业

Group 1 - The core viewpoint is that multiple regions are implementing policies to support the traditional Chinese medicine (TCM) industry, with Zhejiang aiming to cultivate emerging industries like biomedicine, and Henan planning to develop 3-5 TCM companies with annual revenues exceeding 3 billion yuan [1] - The implementation of the "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" on January 27 establishes a unique evaluation system for TCM, combining traditional Chinese medicine theory, human experience, and clinical data, which emphasizes the development path for classic formulas and modified new drugs [1] - The regulations require TCM decoction pieces and formula granule manufacturers to establish a MAH (Marketing Authorization Holder) lifecycle responsibility system to ensure the safety, efficacy, and traceability of TCM [1] Group 2 - The CSI TCM Index (930641) rose by 0.92% as of February 5, 2026, with component stocks such as Darentang increasing by 3.67%, Pian Zai Huang by 3.62%, and Huaren Jiangzhong by 2.03% [1] - The TCM ETF (159647) closely tracks the CSI TCM Index and has shown a 0.92% increase, marking a three-day consecutive rise [1] - As of January 30, 2026, the top ten weighted stocks in the CSI TCM Index include Yunnan Baiyao, Pian Zai Huang, and Tong Ren Tang, collectively accounting for 55.13% of the index [2]